John J. Boyce

Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC.

ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA.

Affomix Corp. was develops and commercializes antibody based products. The company was founded in 2008 and headquartered in Branford, CT.

GnuBIO, Inc. develops life science research and clinical diagnostics products. It develops a droplet-based DNA sequencing technology that integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing to informatics for researchers and clinicians. The company was founded by David A. Weitz, John J. Boyce, IV and Michael P. Weiner and is headquartered in Cambridge, MA.

Genomics Collaborative, Inc. provides clinical samples and applies human genetics to target validation for drug discovery. The company is based in Cambridge, MA. The company was founded by Phyllis I. Gardner and Edward E. Harlow. Genomics Collaborative was acquired by BioServe Biotechnologies Ltd., a SUB of ReproCELL, Inc. from SeraCare Life Sciences, Inc. on May 29, 2007 for $2 million.

Helicos BioSciences Corp. is a life sciences company focused on innovative genetic analysis technologies and the monetization of those technologies and related intellectual property. The company was founded by Stanley N. Lapidus, Stephen D. Quake and Noubar B. Afeyan on May 9, 2003 and is headquartered in Cambridge, MA.

Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023.